Zucara Therapeutics announced highly positive results from its proof-of-concept Phase 1b trial of ZT-01 in people with Type 1 diabetes (“T1D”). Please see the press release here. Why this news is important:
This trial confirms ZT-01’s mechanism of action in restoring glucagon release in patients with T1D.
First-in-class ZT-01, meaningfully restored glucagon release in nearly 90% of treated patients compared to placebo (p<0.0001). This therapy has the potential to become the first therapeutic to prevent hypoglycemia in people with insulin-dependent diabetes.
Positive results from this trial will enable Zucara to further evaluate ZT-01 in a multi-center Phase 2 ...
LSO - Life Sciences Ontario - prepared an in-depth and informative report on the importance of the life science sector in Ontario. TIAP was one of the endorsing organizations. The report was published in May 2021.
On October 9, 2020, the Honourable Mélanie Joly, then Minister of Economic Development and Official Languages and Minister responsible for the Federal Economic Development Agency for Southern Ontario (FedDev Ontario) announced a FedDev Ontario contribution of $6.5 million to Toronto Innovation Acceleration Partners. Read more here: https://bit.ly/3nBEXDR
Under this Agreement, TIAP has to date made the following investments in our portfolio startup companies:
Bitnobi - $15,000, April 1, 2019
Bright Angel Therapeutics - $30,000, August 2, 2019 and $70,000, December 23, 2020
Elarex (McMaster University) - ...
TORONTO, Oct. 3, 2019 /PRNewswire/ -- AmacaThera Inc. (www.amacathera.ca) is pleased to announce the closing of its US $3.6M seed financing round. A first close of the round was led by Sprout BioVentures/ Viva Biotech with participation from Grey Sky Venture Partners, and the round was recently completed with an investment by Toronto-based Lumira Ventures.
Commenting on the closing of the round, Dr. Molly Shoichet, Ph.D., Co-Founder and Chief Scientific Officer of AmacaThera stated: "We are thrilled to have the Lumira team as part ...
In their September 11, 2019 online edition as part of their "Innovation this Week" newsletter, Re$earch Money talked about TIAP's partnership agreement with Amgen:
"A few days after celebrating its 10th anniversary and changing its name to Toronto Innovation Acceleration Partners (TIAP), the commercialization organization formerly known as MaRS Innovation announced a new collaboration with the biotechnology company Amgen. The aim of the collaboration is to identify and jointly fund disruptive technologies derived from discovery research conducted in Toronto and managed by ...
New York, NY and Toronto Canada, Dec. 21, 2017 (GLOBE NEWSWIRE) -- Schrödinger, Inc., a privately-held company dedicated to revolutionizing drug discovery through advanced computational methods, and MaRS Innovation, a non-profit organization supporting the commercialization of research breakthroughs from Toronto’s leading academic institutions, today announced the launch of Bright Angel Therapeutics. The new Toronto-based company is focused on the development of novel therapeutics for treatment of drug-resistant and life-threatening fungal infections. Bright Angel’s first program is based on foundational research from ...
Toronto, August 18, 2016 – Toronto-based ScarX Therapeutics (ScarX) has received approval from Health Canada to begin a Phase I clinical trial of its SCX-001 nefopam cream, a first-of-its-kind topical treatment developed to significantly reduce surgical scarring.
This announcement was covered in Yahoo Finance, The Canadian Business Journal, Global News Wire, and BioSpace.
Applied immediately after surgical wound closure, SCX-001 reduces the amount of scar tissue that develops during the body’s natural healing process. The 24-subject Phase I clinical trial will be conducted at ...
MaRS Innovation was highlighted in the Networks of Centres of Excellence (NCE) newsletter on Wednesday, June 22. The article is titled, "MaRS Innovation revolutionizes approach to commercialization, " and discusses the success of the MaRS Innovation commercialization model.
The article mentions companies such as ScarX Therapeutics, a spin-off of MI and Toronto’s Hospital for Sick Children that is commercializing a topical prescription cream. It also talks about Encycle Therapeutics, a Toronto biotechnology start-up from the University of Toronto, that has developed a fast, ...
UTEST graduate company building a versatile, smart, modular power bar
We've all been there: You reach over behind your TV to plug in yet another device to find your power bar’s out of available outlets. You wonder why your electricity bill’s so high and want to know which appliance is the culprit. You forget to turn something off (or did you?) and you’re already halfway to a meeting.
Knitt Labs, Inc. has developed KnittBar to solve these frustrating problems for those who are ...
Amber Mac from Dx3 Canada interviewed Zack Fisch, CEO and co-founder of DashMD. In the video, Zack discusses DashMD's vision for a better healthcare system and what the company is doing in order to improve the discharge process for patients.
Dash MD seeks to improve the quality of healthcare by providing patients with the necessary tools, information, and resources that they need to successfully traverse their own personal and individualized road to recovery. Their Patient Engagement Platform will be downloadable to patients in ...